Ibtihaj Fughhi1, Tania Campagnoli1, Amjad Ali2, Rami Doukky3,4,5. 1. Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. 2. Division of Cardiology, John H. Stroger, Jr. Hospital of Cook County, 1901 W. Harrison St, Chicago, IL, 60612, USA. 3. Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. rami_doukky@rush.edu. 4. Division of Cardiology, John H. Stroger, Jr. Hospital of Cook County, 1901 W. Harrison St, Chicago, IL, 60612, USA. rami_doukky@rush.edu. 5. Department of Radiology and Nuclear Medicine, Rush University Medical Center, Chicago, IL, USA. rami_doukky@rush.edu.
Abstract
BACKGROUND: In patients undergoing regadenoson SPECT myocardial perfusion imaging (MPI), it is unknown how soon and at which dose intravenous aminophylline can be administered to reverse regadenoson-related adverse effects without blunting stress-induced myocardial ischemia. METHODS AND RESULTS: We analyzed the pooled database of the ASSUAGE and ASSUAGE-CKD trials (n = 548). These were double-blinded, placebo-controlled, randomized clinical trials in which 75 mg of aminophylline or placebo was administered intravenously 90 seconds following 99mTc-tetrofosmin injection. There were no statistically significant differences in summed difference score (SDS) burden (P = .87) and in the rates of myocardial ischemia (SDS ≥ 2) (P = .93) between the aminophylline (n = 274) and placebo (n = 274) groups. There was no interaction between aminophylline use and SDS as a determinant of the composite endpoint of cardiac death or MI (P = .32) or the composite endpoint of cardiac death, MI, or coronary revascularization (P = .92). CONCLUSION: In patients undergoing regadenoson-stress SPECT-MPI, the intravenous administration of 75 mg of aminophylline as early as 90 seconds after radioisotope injection does not seem to attenuate the burden of myocardial ischemia.
RCT Entities:
BACKGROUND: In patients undergoing regadenoson SPECT myocardial perfusion imaging (MPI), it is unknown how soon and at which dose intravenous aminophylline can be administered to reverse regadenoson-related adverse effects without blunting stress-induced myocardial ischemia. METHODS AND RESULTS: We analyzed the pooled database of the ASSUAGE and ASSUAGE-CKD trials (n = 548). These were double-blinded, placebo-controlled, randomized clinical trials in which 75 mg of aminophylline or placebo was administered intravenously 90 seconds following 99mTc-tetrofosmin injection. There were no statistically significant differences in summed difference score (SDS) burden (P = .87) and in the rates of myocardial ischemia (SDS ≥ 2) (P = .93) between the aminophylline (n = 274) and placebo (n = 274) groups. There was no interaction between aminophylline use and SDS as a determinant of the composite endpoint of cardiac death or MI (P = .32) or the composite endpoint of cardiac death, MI, or coronary revascularization (P = .92). CONCLUSION: In patients undergoing regadenoson-stress SPECT-MPI, the intravenous administration of 75 mg of aminophylline as early as 90 seconds after radioisotope injection does not seem to attenuate the burden of myocardial ischemia.
Authors: Z Gao; Z Li; S P Baker; R D Lasley; S Meyer; E Elzein; V Palle; J A Zablocki; B Blackburn; L Belardinelli Journal: J Pharmacol Exp Ther Date: 2001-07 Impact factor: 4.030
Authors: Milena J Henzlova; W Lane Duvall; Andrew J Einstein; Mark I Travin; Hein J Verberne Journal: J Nucl Cardiol Date: 2016-06 Impact factor: 5.952
Authors: Gong Zhao; Axel Linke; Xiaobin Xu; Manuel Ochoa; Francis Belloni; Luiz Belardinelli; Thomas H Hintze Journal: J Pharmacol Exp Ther Date: 2003-09-03 Impact factor: 4.030
Authors: Aiden Abidov; Vasken Dilsizian; Rami Doukky; W Lane Duvall; Christopher Dyke; Michael D Elliott; Fadi G Hage; Milena J Henzlova; Nils P Johnson; Ronald G Schwartz; Gregory S Thomas; Andrew J Einstein Journal: J Cardiovasc Magn Reson Date: 2018-12-20 Impact factor: 5.364